International stem cell corporation announces 2024 fourth quarter and year-end results

San diego, ca / access newswire / march 31, 2025 / international stem cell corporation (otcqb:isco) (www.internationalstemcell.com) ("isco" or "the company"), a california-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on december 31, 2024. fy 2024 financial highlights: revenues increased to $9.09 million in 2024, an increase of 17% compared to $7.79 million in 2023.
STEM Ratings Summary
STEM Quant Ranking